133
Views
3
CrossRef citations to date
0
Altmetric
Letters

Patients with AL amyloidosis and low free light-chain burden have distinct clinical features and outcome

, , , , , , , & show all
Pages 64-65 | Received 15 Nov 2016, Accepted 07 Feb 2017, Published online: 22 Apr 2017

References

  • Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood 2016;128:159–68.
  • Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol 2012;30:4541–9.
  • Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, et al. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 2012;26:2317–25.
  • Fernandez de Larrea C, Verga L, Morbini P, Klersy C, Lavatelli F, Foli A, Obici L, et al. A practical approach to the diagnosis of systemic amyloidoses. Blood 2015;125:2239–44.
  • Brambilla F, Lavatelli F, Di Silvestre D, Valentini V, Rossi R, Palladini G, Obici L, et al. Reliable typing of systemic amyloidoses through proteomic analysis of subcutaneous adipose tissue. Blood 2012;119:1844–7.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.